<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733135</url>
  </required_header>
  <id_info>
    <org_study_id>FHT-P-07-003</org_study_id>
    <nct_id>NCT00733135</nct_id>
  </id_info>
  <brief_title>Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)</brief_title>
  <official_title>Determination of Safety and Effectiveness of the SilverHawk™ Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX™ Embolic Protection Device for the Treatment of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (DEFINITIVE Ca++)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, non-randomized, single arm study of the SilverHawk™ /TurboHawk™
      plaque excision systems when used in conjunction with SpiderFX™ embolic protection device in
      treatment of moderate to severely calcified peripheral arterial disease in the superficial
      femoral and/or popliteal arteries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Revascularization</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>Less than or equal to 50% residual diameter stenosis following plaque excision remaining at the target lesion(s), as adjudicated by the angiographic core laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Event Free Rate 30 Days</measure>
    <time_frame>30 Days</time_frame>
    <description>MAE was defined as a serious adverse event that results in death, acute myocardial infarction, dissection (grade C or greater), clinical perforation, pseudo-aneurysm, thrombosis, distal embolism (clinically relevant), amputation, or clinically-driven target vessel revascularization (TVR), through 30 days post-procedure, as adjudicated by the Clinical Events Committee (CEC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Procedural Success</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>Technical Procedural Success was defined as meeting all of the following requirements:
Less than or equal to 50% residual diameter stenosis at the target lesion(s), as adjudicated by the angiographic core laboratory
No procedure-related Major Adverse Events (MAE), as adjudicated by the Clinical Events Committee (CEC)
No device malfunction causing the procedure to be aborted
Successful delivery and placement of the SpiderFX™ embolic protection device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Diameter Stenosis</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>This endpoint was met when there was less than 30% residual diameter stenosis following treatment with SilverHawk™ /TurboHawk™ plaque excision systems and any adjunctive therapy (if required), as adjudicated by the angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Debris in Deployed SpiderFx™ Embolic Protection Device</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>Presence of debris in deployed SpiderFx™ embolic protection device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of Run-off Distal to the Filter</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>Preservation of run-off distal to SpiderFX™ distal embolic protection device was determined by angiography of run-off vessels at the end of the procedure, as adjudicated by the angiographic core laboratory.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Atherectomy with embolic protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device</intervention_name>
    <description>Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.</description>
    <arm_group_label>Atherectomy with embolic protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides written informed consent

          -  Willing to comply with follow-up evaluations at specified times

          -  Has leg pain due to peripheral arterial disease

          -  Disease located within the femoropopliteal artery

          -  Moderate to severe calcification

        Exclusion Criteria:

          -  Previously implanted stent(s) or stent graft(s) in target leg

          -  Life expectancy less than 12 months

          -  Has any planned surgical or endovascular intervention of target vessel 30 days before
             or after index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Clair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Roberts D, Niazi K, Miller W, Krishnan P, Gammon R, Schreiber T, Shammas NW, Clair D; DEFINITIVE Ca⁺⁺ Investigators. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial. Catheter Cardiovasc Interv. 2014 Aug 1;84(2):236-44. doi: 10.1002/ccd.25384. Epub 2014 Feb 5.</citation>
    <PMID>24402764</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <results_first_submitted>June 5, 2014</results_first_submitted>
  <results_first_submitted_qc>June 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral vascular disease</keyword>
  <keyword>atherectomy</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>calcified lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>133 subjects were enrolled in this study between October 30, 2008 and October 13, 2010. The type of location included hospitals with catheterization labs and/or vascular centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Cohort</title>
          <description>All participants were treated with SilverHawk/TurboHawk atherectomy catheters, with the SpiderFX Embolic Protection Device placed distally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Cohort</title>
          <description>All participants were treated with SilverHawk™ /TurboHawk™ plaque excision systems, with the SpiderFX™ embolic protection device placed distally.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Revascularization</title>
        <description>Less than or equal to 50% residual diameter stenosis following plaque excision remaining at the target lesion(s), as adjudicated by the angiographic core laboratory</description>
        <time_frame>at the end of the procedure</time_frame>
        <population>Number of lesions assessed by the angiographic core lab</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>All participants were treated with SilverHawk/TurboHawk atherectomy catheters, with the SpiderFX Embolic Protection Device placed distally.</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Revascularization</title>
          <description>Less than or equal to 50% residual diameter stenosis following plaque excision remaining at the target lesion(s), as adjudicated by the angiographic core laboratory</description>
          <population>Number of lesions assessed by the angiographic core lab</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="87.6" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>GEE</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Event Free Rate 30 Days</title>
        <description>MAE was defined as a serious adverse event that results in death, acute myocardial infarction, dissection (grade C or greater), clinical perforation, pseudo-aneurysm, thrombosis, distal embolism (clinically relevant), amputation, or clinically-driven target vessel revascularization (TVR), through 30 days post-procedure, as adjudicated by the Clinical Events Committee (CEC).</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>All participants were treated with SilverHawk/TurboHawk atherectomy catheters, with the SpiderFX Embolic Protection Device placed distally.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Event Free Rate 30 Days</title>
          <description>MAE was defined as a serious adverse event that results in death, acute myocardial infarction, dissection (grade C or greater), clinical perforation, pseudo-aneurysm, thrombosis, distal embolism (clinically relevant), amputation, or clinically-driven target vessel revascularization (TVR), through 30 days post-procedure, as adjudicated by the Clinical Events Committee (CEC).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="88.3" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Procedural Success</title>
        <description>Technical Procedural Success was defined as meeting all of the following requirements:
Less than or equal to 50% residual diameter stenosis at the target lesion(s), as adjudicated by the angiographic core laboratory
No procedure-related Major Adverse Events (MAE), as adjudicated by the Clinical Events Committee (CEC)
No device malfunction causing the procedure to be aborted
Successful delivery and placement of the SpiderFX™ embolic protection device</description>
        <time_frame>at the end of the procedure</time_frame>
        <population>Total patient population minus one patient because there was no angiographic post-treatment core lab data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>All participants were treated with SilverHawk/TurboHawk™ plaque excision systems with the SpiderFX™ embolic protection device placed distally.</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Procedural Success</title>
          <description>Technical Procedural Success was defined as meeting all of the following requirements:
Less than or equal to 50% residual diameter stenosis at the target lesion(s), as adjudicated by the angiographic core laboratory
No procedure-related Major Adverse Events (MAE), as adjudicated by the Clinical Events Committee (CEC)
No device malfunction causing the procedure to be aborted
Successful delivery and placement of the SpiderFX™ embolic protection device</description>
          <population>Total patient population minus one patient because there was no angiographic post-treatment core lab data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Diameter Stenosis</title>
        <description>This endpoint was met when there was less than 30% residual diameter stenosis following treatment with SilverHawk™ /TurboHawk™ plaque excision systems and any adjunctive therapy (if required), as adjudicated by the angiographic core laboratory.</description>
        <time_frame>at the end of the procedure</time_frame>
        <population>1 lesion not included because there is no angiographic core laboratory post-treatment data available</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>All participants were treated with SilverHawk™ /TurboHawk™ plaque excision systems, with the SpiderFX™ embolic protection device placed distally.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Diameter Stenosis</title>
          <description>This endpoint was met when there was less than 30% residual diameter stenosis following treatment with SilverHawk™ /TurboHawk™ plaque excision systems and any adjunctive therapy (if required), as adjudicated by the angiographic core laboratory.</description>
          <population>1 lesion not included because there is no angiographic core laboratory post-treatment data available</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Debris in Deployed SpiderFx™ Embolic Protection Device</title>
        <description>Presence of debris in deployed SpiderFx™ embolic protection device</description>
        <time_frame>at the end of the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>All participants were treated with SilverHawk™ /TurboHawk™ plaque excision systems, with the SpiderFX™ embolic protection device placed distally.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Debris in Deployed SpiderFx™ Embolic Protection Device</title>
          <description>Presence of debris in deployed SpiderFx™ embolic protection device</description>
          <units>percentage of deployed filters</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>deployed filters</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preservation of Run-off Distal to the Filter</title>
        <description>Preservation of run-off distal to SpiderFX™ distal embolic protection device was determined by angiography of run-off vessels at the end of the procedure, as adjudicated by the angiographic core laboratory.</description>
        <time_frame>at the end of the procedure</time_frame>
        <population>115/133 subjects had the required angiographic images to assess this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Cohort</title>
            <description>All participants were treated with SilverHawk/TurboHawk atherectomy catheters, with the SpiderFX Embolic Protection Device placed distally.</description>
          </group>
        </group_list>
        <measure>
          <title>Preservation of Run-off Distal to the Filter</title>
          <description>Preservation of run-off distal to SpiderFX™ distal embolic protection device was determined by angiography of run-off vessels at the end of the procedure, as adjudicated by the angiographic core laboratory.</description>
          <population>115/133 subjects had the required angiographic images to assess this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 30 days post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Cohort</title>
          <description>All participants were treated with SilverHawk/TurboHawk atherectomy catheters, with the SpiderFX Embolic Protection Device placed distally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding due to anticoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other, respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Access Site AE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Amputation at or below metatarsal line</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>AV fistula, target vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dissection, grade A or B; target vessel</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dissection, grade D or greater; target vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Distal embolism; plaque, thrombus (blood clot) or debris distal to the filter, clinically relevant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypotension or hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myocardial infarction, acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm, non-target vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Target vessel revascularization; non-clinically driven</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Thrombosis (acute and subacute); target vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vessel clinical perforation, target vessel</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Access site adverse event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dissection, grade A or B; target vessel</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="42" subjects_affected="24" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can not make any publication concerning the study without providing the sponsor 30 days to review it and provide comments. The Sponsor may require PI to delay publication until any factual errors are corrected. If the sponsor determines the proposed publication contains confidential information, or patentable subject matter that requires protection, the sponsor may require delay of the publication less than or equal to 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Medical Communications</name_or_title>
      <organization>Covidien</organization>
      <phone>763-591-3047</phone>
      <email>jean.ahlstrom@covidien.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

